Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
asset turnover
cash per share	0.90 -	0.37 59.24%	32.35 8,758.10%	5.43 83.22%	3.03 44.24%
company equity multiplier	-6.89 -	-0.65 90.59%	1.07 265.16%	1.31 22.65%	1.38 5.15%
days of inventory outstanding
days of payables outstanding
days of sales outstanding
dividend yield
ebit per revenue
ebt per ebit	0.96 -	0.99 3.33%	1.09 9.54%	0.98 10.29%	0.90 8.17%
effective tax rate	0.04 -	0.01 86.67%	-0.07 1,522.65%	0.02 131.28%
enterprise value multiple	-93.92 -	-22.92 75.60%	2.86 112.47%	0.94 67.09%	-1.00 206.13%
fixed asset turnover
free cash flow per share	-0.10 -	-0.52 413.08%	-4.22 707.79%	-2.90 31.37%	-1.94 33.04%
gross profit margin
interest coverage				44.67 -
inventory turnover
long term debt to capitalization	-0.00 -	-0.01 409.50%		0.11 -	0.14 30.95%
net income per ebt	0.96 -	0.99 3.48%	1.07 7.87%	0.98 8.95%	1 2.34%
net profit margin
operating cash flow per share	-0.10 -	-0.46 347.30%	-4.16 812.64%	-2.70 34.98%	-1.77 34.48%
operating profit margin
payables turnover
pretax profit margin
price fair value	-100.93 -	-18.67 81.50%	0.36 101.91%	0.28 22.81%	0.57 107.61%
receivables turnover
return on assets	-0.13 -	-1.26 834.40%	-0.29 76.84%	-0.56 91.64%	-0.42 23.88%
return on capital employed	-0.15 -	-2.00 1,221.97%	-0.27 86.63%	-0.69 157.49%	-0.56 19.14%
return on equity	0.93 -	0.82 12.03%	-0.31 138.25%	-0.73 135.06%	-0.59 19.96%
total debt to capitalization	-0.01 -	-0.05 900.12%	0.00 101.20%	0.11 16,581.63%	0.15 37.82%

COM:PYXISONCOLOGY

Pyxis Oncology, Inc.

Last Close

2.10

22/11 21:00

Market Cap

174.31M

Beta: -

Volume Today

4.13M

Avg: -

Preview